Previous close | 5.08 |
Open | 0.00 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 0.00 - 0.00 |
52-week range | |
Volume | |
Avg. volume | 70,880 |
Market cap | 4.606M |
Beta (5Y monthly) | 0.88 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.71 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
VALNEVA Declaration of shares and voting rights November 30, 2023__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: December 6, 2023 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the change Date on which this chan
Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15 9,437* participants enrolled at sites across the U.S., Europe and Canada in areas where Lyme disease is endemic Trial conclusion expected by year-end 2025Pfizer aims to submit regulatory filings in the U.S. and Europe in 2026 New York, NY, and Saint-Herblain (France), December 4, 2023 – Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that they have
Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ® Primary endpoint met with 97% seroresponse rate 24 months after a single vaccinationAntibody levels remained high and well above the seroresponse threshold, further supporting the anticipated long-term durability of the immune response No safety concerns identified in long-term follow up Saint-Herblain (France), December 4, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty